Wednesday, June 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Nearly 60% of Americans infected by Omicron

by Medical Finance
in Coronavirus
Study: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022. Image Credit: vitstudio / Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

A recent study published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-induced viral antibodies (Abs) seroprevalence in the United States (US).

Study: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022. Image Credit: vitstudio / ShutterstockStudy: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022. Image Credit: vitstudio / Shutterstock

Background

The Omicron (B.1.1.529) variant of SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), became the most common SARS-CoV-2 variant in the US in December 2021. As a result, COVID-19 case rates in the US reached new highs. Since some COVID-19 cases are asymptomatic, undiagnosed, or unreported, traditional disease surveillance techniques do not capture all SARS-CoV-2 cases. Therefore, SASR-CoV-2 seroprevalence assessment, i.e., the percentage of people with SARS-CoV-2 antibodies (Abs), can help researchers better understand the COVID-19 population-level incidence.

About the study

The present paper explored age group-based changes in COVID-19-induced SARS-CoV-2 Abs seroprevalence in the US from September 2021 to February 2022. The team used data from the 2018 American community survey and the CDC’s national commercial laboratory seroprevalence investigation. The national commercial laboratory seroprevalence analysis was a recurrent, cross-sectional nationwide survey that assesses the percentage of the population with SARS-CoV-2 infection-induced Abs in 50 US states, the District of Puerto Rico, and Columbia. 

Anti-nucleocapsid antibodies (anti-N Ab), generated in response to SARS-CoV-2 infection but not in reaction to the presently permitted COVID-19 vaccines, were examined in the collected sera samples. In addition, a convenience blood specimens sample presented for clinical assessment was tested for anti-N Abs every four weeks from September 2021 to February 2022. In February 2022, the sampling timeframe in 18 among the 52 jurisdictions was <2 weeks, while specimens from two jurisdictions were unavailable. To reduce selection bias, specimens for which SARS-CoV-2 antibody testing was ordered by clinicians were excluded.

The investigators calculated the seroprevalence rates over four weeks by age group (≥65, 50–64, 18–49, 12–17, and 0–11 years). Authors used raking spanning age, gender, and metropolitan status characteristics from the 2018 American community survey data to weight jurisdiction-level findings to the population to obtain estimates. Confidence intervals (CIs) were generated using bootstrap resampling, and nonoverlapping CIs were used to assess statistical differences. The Roche Elecsys anti-SARS-CoV-2 pan-immunoglobulin (Ig) immunoassay was used to examine all specimens. Further, R statistics software was used for all statistical analyses.

Results

The study results showed that the median sample size for each four-week term from September 2021 to January 2022 was 73,869 and the sample size for February 2022 was 45,810. Overall, SARS-CoV-2 seroprevalence rose by 0.9 to 1.9 percentage points every four weeks from September to December 2021. 

Seroprevalence of infection-induced SARS-CoV-2 antibodies, by age group — United States, September 2021–February 2022

Seroprevalence of infection-induced SARS-CoV-2 antibodies, by age group — United States, September 2021–February 2022

Moreover, overall COVID-19 seroprevalence in the US rose from 33.5% to 57.7% between December 2021 and February 2022. During the same timestamp, seroprevalence among kids aged 0–11 years went from 44.2% to 75.2%, and among children aged 12–17 years increased from 45.6% to 74.2%. Seroprevalence hiked from 36.5% to 63.7% in individuals aged 18–49 years, 28.8% to 49.8% in adults aged 50–64 years, and 19.1% to 33.2% in adults aged ≥65 years.

As of February 2022, nearly 75% of adolescents and children had serologic evidence of prior COVID-19. In addition, around one-third of this population became newly seropositive after December 2021. From September 2021 to February 2022, the age groups with the least COVID-19 vaccination coverage experienced the highest increases in SARS-CoV-2 seroprevalence. Besides, by April 2022, the percentage of the US population that was fully vaccinated against COVID-19 increased with age (≥65 years, 90%; 50–64, 80%; 18–49, 69%; 12–17, 59%; and 5–11, 28%). Lower SARS-CoV-2 seroprevalence among individuals aged 65 years and older, at higher risk of severe COVID-19, might be linked to increased extra precautions usage among senior citizens.

Conclusions

According to the study, the SARS-CoV-2 Omicron variant had a high infection incidence, especially among children in the US. As the authors noted, seropositivity to anti-SARS-CoV-2 N Ab antibodies should not be construed as immunity to future COVID-19. COVID-19 vaccination remains the safest option for reducing SARS-CoV-2 infection sequelae in children and adults, including COVID-19-linked hospitalization. Following SARS-CoV-2 infection, COVID-19 vaccination offers extra protection against severe illness and hospitalization. 

As a result of the present study, COVID-19 vaccination was significantly beneficial for all eligible individuals, including those who had already been exposed to SARS-CoV-2.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Sustained Release of Co-Amorphous Matrine-Type Alkaloids and Resveratrol with Anti-COVID-19 Potential. Image Credit: PHOTOCREO Michal Bednarek

Study results in three new co-amorphous drug systems with great anti-COVID-19 potential

by Medical Finance
June 29, 2022
0

In a recent study posted in Pharmaceutics, researchers demonstrated that the bioavailability of matrine (MAR)-type alkaloids could be prolonged by...

Study: Sustainable materials and COVID-19 detection biosensor: A brief review. Image Credit: Willyam Bradberry/Shutterstock

Sustainable material-based biosensors for SARS-CoV-2 detection

by Medical Finance
June 29, 2022
0

In a recent study posted to Sensors International, researchers conducted a brief review on biosensors based on sustainable materials for severe...

Study: Time course and epidemiological features of COVID-19 resurgence due to cold-chain food or packaging contamination. Image Credit: Sorn340 Studio Images/Shutterstock

Resurging COVID-19 events related to cold-chain food or packaging contamination

by Medical Finance
June 29, 2022
0

In a recent study published in the latest issue of the Biomedical Journal, researchers reviewed coronavirus disease 2019 (COVID-19) resurgence...

Researchers identify gene expression signatures linked to suicide risk

Covid-19 patients are at increased risk of developing type 2 diabetes, study shows

by Medical Finance
June 29, 2022
0

People who have had Covid-19 are at increased risk of developing type 2 diabetes. This is the result of a...

Study: Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Image Credit:  PIC SNIPE/Shutterstock

Three exposures to SARS-CoV-2 spike protein can induce robust neutralizing antibodies against variants

by Medical Finance
June 29, 2022
0

A recent study conducted by a team of Germany-based scientists has recently revealed that three consecutive exposures to severe acute...

Study: Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern. Image Credit: Gurudev / Shutterstock.com

Study demonstrates substantial immune response in individuals infected with SARS-CoV-2 Omicron variant

by Medical Finance
June 29, 2022
0

The recent emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) has led to...

Next Post
New cryo-EM method may be able to shortcut a big step in modern vaccine development

New cryo-EM method may be able to shortcut a big step in modern vaccine development

Study: Will the COVID-19 pandemic end with the Delta and Omicron variants? Image Credit: G.Tbov/Shutterstock

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) Aged 12–20 Years in the United States Who Received COVID-19 Vaccine, December 2020 through August 2021. Image Credit: Prostock-studio/Shutterstock
    Multisystem inflammatory syndrome in children rare after COVID-19 vaccination in adolescents
  • Study: Efficacy and safety of CVO PLUS CURATIF capsules, Malagasy improved traditional medication for treating COVID-19 a randomized, double-blind, placebo-controlled trial. Image Credit: Andrii Vodolazhskyi/Shutterstock
    Outcomes of phase 3 clinical trial of CVO PLUS CURATIF capsules for COVID-19 treatment
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply